Pfizer Oral Drug, Tofacitinib, for Ulcerative Colitis Meets Key Endpoints in Phase 3 Studies

Pfizer Oral Drug, Tofacitinib, for Ulcerative Colitis Meets Key Endpoints in Phase 3 Studies
Pfizer, Inc., recently announced that its investigational oral drug tofacitinib has met primary and key secondary endpoints in two Phase 3 studies evaluating its efficacy and safety in inducing remission in adult patients with moderately to severely active ulcerative colitis (UC). The results were given in oral presentations at the recent 11th Congress of the European Crohn’s

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *